Azura Ophthalmics Announces Enrollment of First Patient in Phase 3 Clinical Trial for AZR-MD-001 in Patients with Meibomian Gland Dysfunction
Press Release TEL AVIV, Israel – June 4, 2024 – Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that the first patient has been enrolled in the ASTRO study – a Phase 3 clinical trial assessing the efficacy and safety of […]